SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-051638
Filing Date
2020-04-27
Accepted
2020-04-27 16:37:28
Documents
17
Period of Report
2020-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tm2016934d1_8k.htm   iXBRL 8-K 40511
2 EXHIBIT 1.1 tm2016934d1_ex1-1.htm EX-1.1 247356
3 EXHIBIT 5.1 tm2016934d1_ex5-1.htm EX-5.1 9179
4 EXHIBIT 10.1 tm2016934d1_ex10-1.htm EX-10.1 181689
8 GRAPHIC image_001.jpg GRAPHIC 3339
9 GRAPHIC image_002.jpg GRAPHIC 17545
  Complete submission text file 0001104659-20-051638.txt   791127

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA srne-20200427.xsd EX-101.SCH 3222
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20200427_lab.xml EX-101.LAB 34591
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20200427_pre.xml EX-101.PRE 22734
13 EXTRACTED XBRL INSTANCE DOCUMENT tm2016934d1_8k_htm.xml XML 3490
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 20820577
SIC: 2836 Biological Products, (No Diagnostic Substances)